News articles about Scpharmaceuticals (NASDAQ:SCPH) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Scpharmaceuticals earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave press coverage about the company an impact score of 48.370033898694 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
SCPH has been the subject of a number of recent analyst reports. Zacks Investment Research lowered shares of Scpharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Jefferies Group reiterated a “buy” rating and set a $26.00 price target on shares of Scpharmaceuticals in a report on Wednesday, March 21st.
NASDAQ:SCPH traded up $0.05 during midday trading on Wednesday, reaching $11.14. 110,653 shares of the stock traded hands, compared to its average volume of 56,045. Scpharmaceuticals has a 12 month low of $10.52 and a 12 month high of $18.17. The company has a quick ratio of 24.12, a current ratio of 24.12 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $204.99 and a P/E ratio of -1.37.
TRADEMARK VIOLATION WARNING: This story was published by Week Herald and is owned by of Week Herald. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://weekherald.com/2018/04/18/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-scpharmaceuticals-scph-share-price.html.
scPharmaceuticals Inc, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products. The company's under development products are for heart failure and infectious diseases that include Furoscix for the treatment of worsening or decompensated heart failure outside of the inpatient setting.
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.